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Metastasis is a major clinical challenge for cancer
treatment. Emerging evidence suggests that aber-
rant epigenetic modifications contribute significantly
to tumor formation and progression. However, the
drivers and roles of such epigenetic changes in
tumor metastasis are still poorly understood. Using
bioinformatic analysis of human breast cancer
gene-expression data sets, we identified histone de-
methylase RBP2 as a putativemediator of metastatic
progression. By using both human breast cancer
cells and genetically engineered mice, we demon-
strated that RBP2 is critical for breast cancer
metastasis to the lung in multiple in vivo models.
Mechanistically, RBP2 promotes metastasis as a
pleiotropic positive regulator of many metastasis
genes, including TNC. In addition, RBP2 loss sup-
presses tumor formation in MMTV-neu transgenic
mice. These results suggest that therapeutic target-
ing of RBP2 is a potential strategy for inhibition of
tumor progression and metastasis.
INTRODUCTION
In the United States, breast cancer is the most common cancer
and the second leading cause of cancer death in women (De-
Santis et al., 2011). Advanced breast cancer is associated with
significant mortality because it metastasizes to vital organs, pri-
marily to lung, brain, and bone (Bos et al., 2009; Kang et al., 2003;
Minn et al., 2005, 2007). There are still limited treatment options
for patients with metastatic breast cancer. Thus, it is critical to
identify and validate novel drug targets for the development of
effective therapies.
Tumor metastasis is a multistage process that includes local
invasion, intravasation, survival in the circulation, extravasation,
and colonization in distant organs (Nguyen et al., 2009a; Sethi
and Kang, 2011). During this process, cancer cells must over-
come various physiological barriers and adapt to foreign
environments. This requires the coordinatedmodulation of pleio-
tropic genetic programs at different stages of tumor progression868 Cell Reports 6, 868–877, March 13, 2014 ª2014 The Authors(Brabletz, 2012; Peinado et al., 2012). It is conceivable that to
achieve this kind of plasticity, reversible transcription programs
may be required in addition to somatic genetic alterations.
Consistent with this idea, many epigenetic regulators have
been reported to play critical roles in this process (Nguyen and
Massague´, 2007). For example, histone H3K27 methyltransfer-
ase EZH2 and histone demethylase JMJD2C (also known as
KDM4C) were shown to promote tumor progression and metas-
tasis (Luo et al., 2012; Min et al., 2010; Varambally et al., 2002). In
contrast, histone H3K4 demethylase LSD1 was reported to
inhibit breast cancer metastasis (Wang et al., 2009b).
Breast cancer metastasis to different tissues is mediated in
part by organ-specific metastasis genes, some of which are
also highly expressed in the primary tumors. Some of these
genes, such as MMP1 and CXCL1, provide growth advantages
in both the primary and metastatic sites, whereas others, such
as TNC andMMP2, promote aggressive growth only in the met-
astatic niche (Minn et al., 2007). Despite their known functions,
the mechanisms by which these genes are upregulated remain
unknown. These gene products can be modulated individually
or more broadly by pleiotropic regulators, including transcription
factors and epigenetic regulators. Although transcription factors
are difficult to target, epigenetic regulators are very attractive tar-
gets for cancer therapies, in part because epigenetic changes
are reversible (Blair and Yan, 2012; Rodrı´guez-Paredes and
Esteller, 2011).
To identify epigenetic regulators that can be targeted in breast
cancer metastasis, we conducted an unbiased bioinformatic
analysis of human breast cancer data sets. We identified a
strong association between the expression of histone demethy-
lase RBP2 (also known as JARID1A andKDM5A) and breast can-
cer metastasis. RBP2 is a member of the JARID1 family histone
demethylases, which catalyze the removal ofmethyl groups from
tri- or dimethylated lysine 4 in histone H3 (Blair et al., 2011; Chris-
tensen et al., 2007; Iwase et al., 2007; Klose et al., 2007; Lee
et al., 2007; Secombe et al., 2007; Tahiliani et al., 2007; Yamane
et al., 2007). We showed that RBP2 positively regulates many
metastasis-related genes, including TNC, which is required for
metastatic colonization in the lungs. These findings were further
validated in the MMTV-neu transgenic mouse model. Impor-
tantly, RBP2 promotes TNC expression and malignant invasion
through a demethylase-independent mechanism. In summary,
our findings suggest that RBP2 regulates a critical epigenetic
Figure 1. A High RBP2 Expression Level Is Associated with Breast
Cancer Metastasis
(A) Correlation of the mRNA levels of histone-modifying enzymes with breast
cancer metastasis. The patients were divided into two groups with either
higher or lower expression based on each probe. Plotted are the hazard ratio
(HR) with 95% confidence and the Bonferroni multiple-testing-corrected
p value (MTCPV).
(B) Kaplan-Meier analysis of metastasis-free survival of lymph-node-negative
patients with breast cancer, stratified by RBP2 expression level based on the
202040_s_at probe.
(C) Summary of the Kaplan-Meier analysis of metastasis-free survival of all
patients and ER+ or ER breast cancer patients in the EMC286 cohort.
(D) Western blot analysis of RBP2 and tubulin in the indicated cells. 231, MDA-
MB-231 cells.
See also Figure S1 and Tables S1 and S2.switch that sets the stage for tumor metastasis and can be tar-
geted to inhibit breast cancer progression and metastasis.
RESULTS
RBP2 Expression Is Strongly Associated with Breast
Cancer Metastasis
To identify epigenetic regulators of breast cancer metastasis, we
conducted an unbiased bioinformatic analysis of gene-expres-
sion profiles of mammary tumors from 533 breast cancer
patients by using Kaplan-Meier Plotter, a meta-analysis-based
biomarker assessment tool (Gyo¨rffy et al., 2010). This analysis
tool utilizes Affymetrix gene-expression profiling data, which
have multiple probe sets for most genes. We examined the
correlation between increased incidence of distant tumormetas-
tasis with the gene-expression levels of a comprehensive list of
targetable histone methylation and acetylation enzymes,
including histone lysine methyltransferases (KMTs), histone
lysine demethylases (KDMs), histone acetyltransferases
(KATs), and histone deacetylases (HDACs). This analysis re-
vealed that high mRNA levels of two enzymes, EZH2 and
RBP2, correlated significantly with early and high incidence of
tumor metastasis (Figure 1A; Table S1). Our approach was vali-
dated by the fact that EZH2 (only one probe available) was pre-
viously shown to promote invasion andmetastasis of breast can-
cer cells (Kleer et al., 2003; Moore et al., 2013). Two probes of
RBP2 are present on the microarray platform, and both probes
showed similar results (Figures 1B and S1A). RBP2 was previ-ously found to promote tumorigenesis (Lin et al., 2011; Zeng
et al., 2010) and drug resistance (Sharma et al., 2010). However,
the role of RBP2 in breast cancer metastasis has not been stud-
ied. Therefore, we focused on the role of RBP2 in breast cancer
metastasis.
We validated the association of RBP2 expression with breast
cancer metastasis using a large clinical data set, EMC286 (Fig-
ure S1B). To determine whether the association of RBP2 expres-
sion with metastasis is subtype specific, we performed an inde-
pendent analysis of estrogen receptor (ER)-positive (ER+) and
-negative (ER) patients. This revealed that RBP2 expression
was strongly associated with metastasis in ER patients in
both the EMC286 and combined data sets, but wasmore weakly
associated with metastasis in ER+ patients only in the combined
data set (Figures 1C and S1C–S1I). To further determine whether
RBP2 can be an independent clinical indicator of metastasis, we
conducted a Cox multivariate analysis of EMC286. Our analysis
indicated that RBP2 was associated with tumor metastasis
independently of ER, progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) status (Table S2).
We then extended our analysis to the MDA-MB-231 and the
4T1 breast cancer cell line series. LM2 and 1833 cells were
derived from ER MDA-MB-231 human breast cancer cells by
in vivo selection, and have increased metastatic activity to the
lungs or bones, respectively, when compared with their parental
cells (Kang et al., 2003; Minn et al., 2005). The mouse mammary
tumor cell lines 67NR, 168FARN, 4TO7, 66cl4, and 4T1 were iso-
lated from a single spontaneous mammary tumor and have vary-
ing abilities to metastasize to the lungs (Aslakson and Miller,
1992). Western blot analysis showed that RBP2 protein was ex-
pressed at a higher level in the more lung-metastatic LM2 cells
compared with the bone-metastatic 1833 cells or the less meta-
static parental MDA-MB-231 cells (Figure 1D). Furthermore, the
expression levels of RBP2 correlated strongly with the metasta-
tic capabilities of the 4T1 series, with RBP2 levels being highest
in the most aggressive 4T1 cell line (Figure 1D). These results are
consistent with our observation in patient samples that the RBP2
expression level correlated with increased metastatic potential.
RBP2 Is Critical for Prometastatic Gene Expression
To determine the roles of RBP2 in breast cancer, we transfected
MDA-MB-231 cells with small interfering RNA (siRNA) against
RBP2 or a siRNA control. We found that knockdown of RBP2
led to a global increase of H3K4me3 levels, suggesting that
RBP2 is the major H3K4me3 demethylase in MDA-MB-231 cells
(Figures S2A and S2B). To determine the effects of RBP2 deple-
tion on gene expression, we conducted microarray analysis of
these cells and identified 176 upregulated and 212 downregu-
lated genes after RBP2 knockdown (Table S3). Next, we per-
formed gene set enrichment analysis (GSEA) (Subramanian
et al., 2005) to determine whether RBP2 loss causes alterations
of known breast cancer organotropic metastasis gene signa-
tures, including the lung-metastasis signature (LMS), bone-
metastasis signature (BoMS), and brain-metastasis signature
(BrMS) (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005,
2007). These analyses revealed that RBP2 knockdown signifi-
cantly decreased the expression of genes linked to breast can-
cer metastasis to the lungs (Figure 2A). In contrast, there wereCell Reports 6, 868–877, March 13, 2014 ª2014 The Authors 869
Figure 3. Knockdown of RBP2 Reduces Cell Invasion In Vitro
(A and B) Representative image of DAPI staining (A) and quantification of LM2
cells (B) that invaded through Matrigel-coated membrane inserts after treat-
ment with the indicated siRNA.
(C) Western blot analysis of the indicated proteins in whole-cell lysates or
conditioned media of MDA-MB-231 (231) and LM2 cells transfected with the
indicated siRNAs.
(D) Quantification of LM2 cells that invaded through Matrigel-coated mem-
brane inserts after transfection with the indicated siRNAs and treatment with
the indicated concentration of recombinant TNC protein.
(B and D) Four random fields of each insert were quantified and normalized to
the control. Error bars represent the SEM of three inserts. **p < 0.01; ***p <
0.001. Luc, luciferase siRNA; Scr, scrambled siRNA, RBP2 si-1, RBP2
siRNA-1; RBP2 si-2, RBP2 siRNA-2.
See also Figure S3.
Figure 2. RBP2Regulates the Expression of Lung-Metastasis Genes
(A) GSEAs of MDA-MB-231 cells with RBP2 siRNAs versus control siRNA
using organ-specific metastasis gene signatures. Left panel: enrichment plot
showing decreased enrichment of the lung-metastasis gene signature inMDA-
MB-231 cells transfected with RBP2 siRNA compared with those with control
siRNA. Right panel: summary of enrichment analyses. Shown are normalized
enrichment scores (NES), nominal p value (p-val), and false discovery rate
q value (q-val). RBP2 KD, RBP2 siRNA knockdown; Ctrl KD, control siRNA
knockdown. LMS, lung-metastasis signature; BoMS, bone-metastasis
signature; BrMS, brain-metastasis signature; Up, upregulated genes; Down,
downregulated genes.
(B) Real-time RT-PCR analysis of the indicated mRNAs in MDA-MB-231 (231)
or LM2 cells transfected with scrambled control or RBP2 siRNA. Scr si,
scrambled siRNA; RBP2 si-1, RBP2 siRNA-1; RBP2 si-2, RBP2 siRNA-2. Error
bars represent SD.
See also Figure S2 and Table S3.no significant changes in genes involved in breast cancer metas-
tasis to the bone or brain in RBP2 knockdown cells (Figure 2A,
right panel). This result is consistent with our observations that
RBP2 is highly expressed in the lung-metastatic LM2 cells, but
not in the bone-metastatic 1833 cells.
To confirm these results by real-time RT-PCR analysis, we
selected TNC, SOX4, FSCN1, PDGFA, SERPINE2, and PLCB1,
all of which have been implicated in breast cancer metastasis
to the lungs (Minn et al., 2005, 2007; Tavazoie et al., 2008; Tiwari
et al., 2013). As expected, all of these genes were expressed
at higher levels in LM2 cells compared with MDA-MB-231 cells
(Figure 2B). Consistent with our GSEA results, RBP2 knock-
down led to significant downregulation of all of these genes
in MDA-MB-231 cells and most of these genes in LM2 cells
(Figure 2B).
RBP2 Regulates Breast Cancer Cell Invasion through
TNC
Invasion of tissue basement membranes is one of the key steps
of metastasis. To dissect the roles of RBP2 in tumor metastasis,
we first examined its role in invasion using Transwell invasion as-870 Cell Reports 6, 868–877, March 13, 2014 ª2014 The Authorssays. LM2 cells, which expressed higher levels of RBP2, showed
increased invasion ability compared with MDA-MB-231 cells
(Figure S3A). Furthermore, we found that LM2 cells transfected
with siRNAs against RBP2 showed a dramatic decrease in inva-
sion ability compared with cells transfected with the control
siRNAs (Figures 3A and 3B).
TNC, which encodes tenascin C, was the most significantly
decreased metastasis gene in LM2 cells with RBP2 knockdown.
TNC is an extracellular matrix protein that enhances cancer cell
migration and invasion (Hancox et al., 2009; Nagaharu et al.,
2011). TNC also promotes colonization of breast cancer cells to
the lungsand isacritical componentof themetastaticniche invivo
(Oskarssonet al., 2011). Therefore,we further examined the regu-
lationof TNCasanoutput forepigeneticmodulationof invasionby
RBP2. We analyzed protein levels in the media of LM2 cells and
confirmed that extracellular TNC protein production was also
regulatedbyRBP2 (Figure 3C).Next,we examined thecorrelation
of RBP2 and TNC expression in human primary breast tumors.
Consistent with our data from the cell lines, ER tumors with
high levels of RBP2 expressed high levels of TNC (Figure S3B).
Figure 4. RBP2 Promotes TNC Expression and Cell Invasion in a
Demethylase-Independent Manner
(A andB)Western blot analysis of the indicated proteins inwhole-cell lysates or
conditioned media of LM2 cells cotransfected with the indicated siRNAs and
plasmids.
(C and D) Quantification of LM2 cells that invaded through Matrigel-coated
membrane inserts after transfection with the indicated siRNAs and plasmids.
Scr si or Scr, scrambled siRNA, RBP2 si-1, RBP2 siRNA-1; RBP2 si-4, RBP2
siRNA-4; EV, empty vector plasmid; WT, wild-type RBP2 plasmid; HA-RBP2,
HA-RBP2 plasmid; HA-RBP2H483A, HA-RBP2 plasmid with H483Amutation;
VSVG-RBP2, VSVG-RBP2 plasmids. A schematic map of VSVG-RBP2 plas-
mids is shown in Figure S4C. Error bars represent the SEM of three inserts.Since we showed that TNC expression is regulated by RBP2,
we next tested whether TNC is required for the proinvasive func-
tion of RBP2. To that end, we added recombinant TNC protein
into the chambers in Transwell assays. The addition of TNC
partially rescued the decreased invasion phenotype in RBP2
knockdown cells (Figure 3D), suggesting that regulation of inva-
sion by RBP2 was at least partially due to the decrease of TNC
expression in RBP2 knockdown cells.
RBP2 Promotes TNC Expression and Invasion
in a Demethylase-Independent Manner
To dissect the mechanism by which RBP regulates gene expres-
sion and invasion, we reintroduced siRNA-resistant forms of
RBP2 into RBP2 knockdown cells. Consistent with the idea
that RBP2 is critical for TNC expression, restoration of wild-
type RBP2 expression rescued the TNC level in RBP2 knock-
down cells (Figure 4A). Interestingly, reintroduction of a histone
demethylase-defective form of RBP2 (RBP2 H483A) also
rescued the decrease of TNC (Figure 4A). Moreover, chromatin
immunoprecipitation (ChIP) assays showed that knockdown of
RBP2 in LM2 cells led to only a slightly decrease of H3K4me3
near the TNC transcriptional start site (Figures S4A and S4B).
These results suggest that the demethylase activity of RBP2 is
not required for TNC expression in LM2 cells.
To further investigate whether other RBP2 domains are
required for TNC expression, we tested the effects of expressingRBP2 truncation mutants in LM2 cells transfected with an siRNA
targeting 30 UTR of RBP2. We found that RBP2 mutants lacking
either the N- or C-terminal domains failed to rescue TNC expres-
sion (Figures 4B and S4C), suggesting that the N- and C-terminal
domains are required for TNC expression in LM2 cells. To deter-
mine if TNC is a direct target of RBP2, we performedChIP assays
using an anti-RBP2 antibody. Despite strong enrichment of
RBP2 at the promoter of a known RBP2 target gene NDUFA9,
we did not detect RBP2 binding at the TNC promoter (Fig-
ure S4D). Hence, RBP2 does not regulate expression of TNC
by modulating its promoter activity.
Next, we determined the abilities of wild-type and mutant
RBP2 to promote invasion. Reintroduction of either wild-type
or a demethylase-defective RBP2 in LM2 cells rescued the
diminished cell invasion induced by RBP2 knockdown (Fig-
ure 4C). In contrast, an N-terminal truncated form of RBP2 was
unable to rescue the decreased invasion ability of LM2 cells
caused by RBP2 knockdown (Figure 4D), suggesting that the
N-terminal domains, but not the histone demethylase activity
of RBP2, are required to promote cell invasion.
RBP2 Is Critical for Breast Cancer Metastasis to the
Lungs In Vivo
To investigate the roles of RBP2 in metastasis in vivo, we gener-
ated LM2 cells with a scrambled small hairpin RNA (shRNA) con-
trol hairpin or stable knockdown of RBP2 using two independent
shRNA hairpins. LM2 cells were engineered to express firefly
luciferase (Minn et al., 2005), which allows for live imaging of
metastasis in vivo. Similar to our results from siRNA-mediated
knockdown, LM2 cells with RBP2 stable knockdown secreted
lower levels of TNC compared with the control cells (Figure S5A).
Cells with stable RBP2 knockdown and their respective control
cell line were then injected into the tail vein of NOD.SCID mice.
Lungmetastatic activity was assayed by bioluminescence imag-
ing weekly, as well as by examination of the lungs at necropsy.
RBP2 knockdown led to an approximately 10-fold decrease in
the lung-metastasis abilities of LM2 cells (Figures 5A and 5B).
This effect was observed even at the early time points (Figures
5A and 5B), suggesting that RBP2 controls extravasation and/or
early seeding of lung metastasis in vivo. Histological analysis of
the lungs isolated at necropsy confirmed that mice injected with
RBP2 knockdown cells had fewer and smaller lesions in the
lungs (Figure 5C).
To determine whether RBP2 more broadly affects tumor pro-
gression or metastasis to multiple organs in vivo, we performed
stable RBP2 knockdown in the bone-selective 1833 breast can-
cer cell lines. Knockdown of RBP2 in 1833 cells had no signifi-
cant effect on the ability of these cells to colonize the bone
(Figures 5D and S5B). Knockdown of RBP2 also showed no
effect on mammary tumor formation following orthotopic trans-
plantation of LM2 cells into themammary gland (Figure 5E). Alto-
gether, these in vivo results are consistent with the observation
that RBP2 regulates the expression of genes specific for lung
metastasis.
To further validate our findings in a genetically engineered
mouse model, we examined the effects of RBP2 loss on breast
cancer progression and metastasis usingMMTV-neu transgenic
mice, a breast cancer mouse model in which >70% of mice withCell Reports 6, 868–877, March 13, 2014 ª2014 The Authors 871
Figure 5. Knockdown of RBP2 Decreases Tumor Metastasis In Vivo
(A and B) Normalized bioluminescence signals of lung metastasis and representative bioluminescence images of mice injected intravenously with LM2 cells
stably expressing control or RBP2 shRNA. The data represent average ± SEM. *p < 0.05; ***p < 0.001.
(C) Representative hematoxylin and eosin (H&E)-stained lung sections. Mice injected with LM2 cells carrying control shRNA (Control sh) have more tumors
(panels 1 [*not all tumor foci marked] and 3) than mice with LM2 cells carrying RBP2 shRNA (RBP2 sh-1; panels 2 [arrowheads] and 4) visible at low power.
Vascular invasion (panel 3, arrow) and small foci of metastatic nodules (panel 4, arrows) are observed at increased magnification. Scale bars, 500 mm (panels 1
and 2) and 100 mm (panels 3 and 4).
(D) Normalized bioluminescence signals of bone metastasis and representative bioluminescence images of mice injected intracardially with 1833 cells stably
expressing control or RBP2 shRNA. The data represent average ± SEM; n.s., nonsignificant.
(E) The average weight of primary tumors at the endpoint in mice implanted in mammary fat pads with LM2 cells stably expressing control or RBP2 shRNA. Ctrl sh
or Ctrl, control shRNA; Sh-1, RBP2 sh-1. Error bars represent SEM.
See also Figure S5.mammary tumors were previously shown to develop lung
metastases (Guy et al., 1992). These mice carry wild-type neu
(the rat HER2 gene) under the control of the mouse mammary
tumor virus (MMTV) promoter. We crossed the Rbp2 knockout
mice with the MMTV-neu transgenic mice and monitored mam-
mary tumor formation and lung metastasis. We found that Rbp2
knockout delayed mammary tumor formation in the MMTV-neu
mice (Figure 6A), suggesting that RBP2 can contribute to mam-
mary tumor development in this model. Lungs were obtained
from mice when their primary mammary tumors were of similar872 Cell Reports 6, 868–877, March 13, 2014 ª2014 The Authorssize and reached approximately 1 cm3 (Figure S6). Similar to
the results obtained from the experimental lung colonization
model, the Rbp2 knockout mice showed a dramatic decrease
in the number of lung-metastasis nodules and the incidence of
lung metastasis (Figures 6B–6D). Interestingly, in this model,
most of the lung-metastasis nodules were located inside the
blood vessels, suggesting that RBP2 can also mediate the sur-
vival and proliferation of breast cancer cells in the pulmonary
vasculature. Taken together, our findings from the human cell
line models, preclinical mouse models, and patient tumor
Figure 6. Loss of RBP2 Decreases Tumor Progression and Metastasis in MMTV-neu Transgenic Mice
(A) Kaplan-Meier tumor-free survival curves ofMMTV-neu transgenic mice with the indicated genotypes of Rbp2. N, number of animals in each group; M, days of
median survival in each group. p < 0.0001 based on log rank (Mental-Cox) test.
(B) Column scatterplot showing the number of lung-metastatic nodules in MMTV-neu transgenic mice with the indicated Rbp2 genotypes.
(C) Incidence of lung metastasis in MMTV-neu transgenic mice with the indicated Rbp2 genotypes.
(D) Representative H&E-stained lung sections. Rbp2+/+:MMTV-neu mice (panels 1, 3, and 5) show more tumors in the lungs than Rbp2/:MMTV-neu mice
(panels 2, 4, and 6), and the morphologies of the tumor cells are similar (panels 5 and 6). Scale bars, 500 mm (panels 1–4) and 100 mm (panels 5 and 6).
See also Figure S6.samples strongly support a role for RBP2 as an epigenetic driver
of metastasis.
DISCUSSION
By mining the gene-expression profiles of human mammary
tumors, we identified a strong association of RBP2 expression
with breast cancer metastasis. Consistent with this finding, we
found that RBP2 is overexpressed in highly metastatic cell lines
that were generated from both human andmouse breast tumors.
We revealed that RBP2 has pleiotropic roles in invasion and
metastasis, and linked RBP2 function to the regulation of several
well-known genetic mediators of metastasis. Although recent
studies highlighted the connection between epigenetic regula-
tors and tumor metastasis, those studies were mostly limited
to experiments using cancer cell lines or mouse xenograft
models (Cao and Yan, 2013). Our study is bolstered by functional
data from several preclinical mouse models, which demonstratethat RBP2 is a critical epigenetic mediator of metastasis and an
ideal cancer target. Combinedwith our analysis of human patient
data, these results provide a strong rationale for targeting RBP2
to treat invasive and metastatic breast cancer.
Using two independent bioinformatic pipelines, we showed
that the RBP2 level correlated with an increased incidence of
breast cancer metastasis. However, a recent report using
GOBO (gene expression-based outcome for breast cancer
online; Ringne´r et al., 2011) showed that the RBP2 level corre-
lated with increased relapse-free survival (Paolicchi et al.,
2013), although no functional experiments were performed to
validate that result. This discrepancy could be due to the
different cohort sizes and methods of analysis used. Kaplan-
Meier Plotter for our analysis included more comprehensive
gene-expression profiles of 2,977 nonredundant breast tumors
(Gyo¨rffy et al., 2010), whereas GOBO included 1,881 breast
tumors (Ringne´r et al., 2011). In contrast to the one data-normal-
ization step used by GOBO, our analysis also incorporated twoCell Reports 6, 868–877, March 13, 2014 ª2014 The Authors 873
data-normalization steps and was independently validated.
Therefore, the results from the previous study may have been
more sensitive to data set inclusion and sample stratification.
The inconsistency between these data sets requires further func-
tional validation using cell-based assays andmousemodels. Our
extensive functional studies clearly validated our bioinformatic
analysis, highlighting the importance of functional validation.
RBP2 has been implicated as an oncoprotein in various cancer
types (Blair et al., 2011; Sharma et al., 2010). For example, it was
reported that RBP2 amplification is found in approximately 15%
of breast cancers (Hou et al., 2012). We previously showed that
RBP2 is critical for endocrine tumor formation in mice lacking
Rb and menin tumor suppressors (Lin et al., 2011). In this study,
using two in vivo metastasis models, we demonstrated that
knockdown or loss of RBP2 inhibits breast cancer metastasis
to the lungs. In contrast, RBP2 is not required for bonemetastasis
by 1833 cells. These results highlight the critical role of a pleio-
tropic epigenetic regulator in directing the transcription program
of tissue-specificmetastasis. AlthoughRBP2 knockdowndid not
affect the rate of primary tumor growth by LM2 cells in the ortho-
topic xenograft model, Rbp2 loss inhibited primary tumor forma-
tion in the MMTV-neu model. These results suggest that RBP2
likely regulates early stages of tumor progression when overex-
pressed early on in the mammary gland, or promotes a more
amenable mammary tumor microenvironment for early tumori-
genesis. Therefore, our studies highlight the importance of tar-
getingRBP2both in early tumorigenesis and in tumormetastasis.
ER breast cancer is an aggressive subtype of breast cancer
that is often associated with rapid and frequent metastasis and
poor patient outcome (Carey et al., 2010). However, only a
limited number of targeted therapeutic methods for patients
with this type of breast cancer are currently under investigation
in the clinic. Here, we demonstrated that RBP2 is critical for inva-
sion and metastasis of ER breast cancer cells. Suppression of
tumor formation and metastasis by Rbp2 loss in the MMTV-neu
model suggests that RBP2 is also critical for breast cancer
metastasis in HER2+ patients, the majority of whom are also
ER. These findings are consistent with our results from human
patient samples, which showed that RBP2 was strongly associ-
ated with increased metastasis in ER patients. Taken together,
these results support the requirement of RBP2 in aggressive
breast cancers and provide a rationale for novel treatment
methods targeting RBP2 in ER and HER2+ patients.
Our gene-expression analyses showed that RBP2 is a pleio-
tropic positive regulator of lung-metastasis genes, suggesting
that RBP2 is a critical epigenetic switch that enables tumor cells
to metastasize by activating a constellation of genes. Contrary to
the prevailing notion that RBP2 can only repress gene expression
through histone demethylation, RBP2 has diverse activities in
gene regulation and can activate gene expression (Benevolen-
skaya et al., 2005; Wang et al., 2009a). Consistent with its role
in gene activation, our mechanistic studies indicated that RBP2
promotes TNC expression and cell invasion via a demethylase-
independentmechanism.Similar toour findings, itwaspreviously
shown that Lid, the fly homolog of RBP2, has a demethylase-
independent function in dMyc-mediated cell growth and devel-
opment (Li et al., 2010). Furthermore, our results also indicated
that theN- andC-terminal domainsofRBP2are required for regu-874 Cell Reports 6, 868–877, March 13, 2014 ª2014 The Authorslation of TNC expression, and the N-terminal domains of RBP2
are required for cell invasion. The ARID domain located in the N
terminusofRBP2 is involved inDNAbinding (Tuet al., 2008),while
the LXCXEmotif located in the C terminus of RBP2 interacts with
Rbandp107 (Defeo-Joneset al., 1991;Kimet al., 1994). Thus, our
results suggest that DNA binding and recruitment of Rb or p107
by RBP2 may be required for activation of RBP2 target genes,
such as TNC. In contrast, RBP2 demethylase activity was re-
ported to promote proliferation of mouse embryonic fibroblasts
(Lin et al., 2011) and growth and invasion of lung cancer cells
(Teng et al., 2013). Although demethylase inhibitors such as the
small molecules we identified recently (Sayegh et al., 2013) could
be used to suppress cancer progression in general, our results
suggest that an alternative targeting strategy is needed to inhibit
invasion and metastasis by breast cancer cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Transwell Invasion Assays
MDA-MB-231 and 4T1 breast cancer cell series were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum and
1%penicillin and streptomycin. Retrovirusesweregeneratedbycotransfection
of pLKO.1 plasmids carrying the indicated shRNAs with packaging plasmids
into 293T cells as described previously (Klose et al., 2007). To generate
RBP2 stable knockdown cell lines, LM2 cells were infected with the indicated
viruses and selected with 1 mg/ml puromycin for 2 weeks. siRNA transfections
were performed using RNAiMAX (Invitrogen). Plasmid transfections and
plasmid/siRNA cotransfections were performed using Lipofectamine 2000
(Invitrogen). The shRNA sequences targeting RBP2 were as follows: sh-1,
ccagacttacagggacactta; and sh-2, ccttgaaagaagccttacaaa. Scrambled con-
trol shRNA was described previously (Yang et al., 2007). The siRNA targeting
sequences of RBP2were as follows: siRNA-1, gctgtacgagagtatacac; siRNA-2,
cttctgtactgctgactgg; siRNA-3, gccaagaacattccagcct; and siRNA-4, gatagtagt
tagaggctta, which targets the 30 UTR of RBP2. Scrambled siRNA was
described previously (Beshiri et al., 2012) and luciferase siRNA was obtained
from Dharmacon. The pcDNA3/HA-RBP2 construct was described previously
(Benevolenskaya et al., 2005) and the H483Amutation was introduced by site-
directedmutagenesis asdescribedpreviously (Kloseet al., 2007). ThepCI-neo/
VSVG-RBP2 constructs were described previously (Chan and Hong, 2001).
The Transwell invasion assay was performed as described previously (Cheung
et al., 2013). Pictures of four random fields from eachwell were taken under the
microscope at 103 magnification, and the number of cells on the basal side
was counted. In the TNC rescue experiment, BSA and/or recombinant TNC
protein (CC065; Millipore) were preincubated with the insert for 2 hr and added
to the media when cells were seeded at a final concentration of 100 ng/ml.
Animal Studies
Female NOD.SCID mice (6–8 weeks old) were used for lung-metastasis and
mammary fat pad tumor growth experiments. Male athymic nude mice (4–
6 weeks old) were used for bone-metastasis experiments. For the lung-metas-
tasis assay, 23 105 viable cells were resuspended in 0.1 ml saline and injected
into the lateral tail vein. For the bone-metastasis assay, 1 3 105 viable cells
were resuspended in 0.1 ml saline and injected into the left ventricle of the
heart. Lung- or bone-metastatic colonization was monitored and quantified
immediately after the injection and at the indicated time points using noninva-
sive bioluminescence, and validated at the endpoint by histological analysis as
previously described (Bos et al., 2009; Lu et al., 2011; Nguyen et al., 2009b). All
values of luminescence photon flux were normalized to the value of the same
mouse obtained immediately after injection of the cells. For the mammary fat
pad tumor growth assay, 1 3 106 viable cells were resuspended in 0.1 ml of a
1:1 mixture of saline and Matrigel, and injected into the fat pads of the 4th
mammary glands. Tumor weight was determined at the endpoint.
MMTV-neu (FVB/N-Tg(MMTVneu)202Mul/J) mice were obtained from The
Jackson Laboratory. Rbp2/ mice (Klose et al., 2007) were backcrossed to
the FVB background for at least eight generations and then crossed with the
MMTV-neu transgenic mice for two generations. The copy numbers of the
MMTV-neu transgene were determined by genotyping at least 12 offspring
from the crossing of Rbp2+/ mice carrying the MMTV-neu transgene with
wild-type mice. Rbp2+/ mice with two copies of the MMTV-neu transgenes
were selected and intercrossed. Breast tumor formation in Rbp2+/+:MMTV-
neu and Rbp2/:MMTV-neu mice was monitored weekly and the mice were
euthanizedwhen primary tumors reached approximately 1 cm3. All procedures
involving animals were approved by the Institutional Animal Care and Use
Committee of Yale University.
Bioinformatic and Statistical Analysis
Kaplan-Meier Plotter analysis of histone-modifying enzymes in metastasis-
free survival of breast cancer patients was performed by using the tool gener-
ated by Gyo¨rffy et al. (2010). The following settings were used for the analysis:
distant metastasis-free survival, autoselect best cutoff, 10 years follow-up
threshold, ER status all, PR status all, lymph-node negative, grade all, and
molecular subtype all. Multiple-testing-corrected p values of each probe
were calculated by timing the original p value with the number of genes
analyzed (n = 69). The results of these experiments are described in Figures
1A, 1B, S1A, S1C–S1E, S1G, and S1H and Table S1.
EMC286 cohort gene-expression data were downloaded from GSE2034
(Wang et al., 2005) and normalized using the robust multiarray average method
within the R Affy package. For this cohort, the RBP2 probe 202040_s_at was
selected forKaplan-Meiermetastasis-freesurvival analysisandcorrelationanal-
ysis. Samples with high, medium, and low RBP2 expression levels were clus-
tered using the quartile or k-means as indicated in the figure legends. Metas-
tasis-free survival plots and Cox univariate and multivariate metastasis-free
survival analyses were performed using the R survival package. The Pearson
correlation test wasperformedusing the cor.test R function. The results of these
experiments are described in Figures 1C, S1B, S1F, S1I, and S3B and Table S2.
Triplicate total RNA samples were isolated from MDA-MB-231 cells 72 hr
after transfectionwith siRNAsagainstRBP2or luciferasecontrol.Gene-expres-
sion profiling was performed by the Yale Center for Genome Analysis using the
HumanHT-12 V3.0 Expression Beadchip Kit (BD-103-0203, Illumina). Nonnor-
malized gene-expression profiling data exported from Illumina Genome Studio
were processed using the Lumi R package. The LimmaR packagewas used to
generate a differential expressed-gene list by comparing the average of two
RBP2 knockdown (RBP2 siRNA-1 and siRNA-2) samples with the control
knockdown (luciferase siRNA) samples. Using an adjusted p value of <0.05
and >1.5-fold difference as the cutoff, we found that 176 genes were upregu-
lated and 212 were downregulated after RBP2 knockdown. The raw data
were deposited in the NCBI Gene Expression Omnibus database under acces-
sion number GSE49119. The gene-expression profiles of the control knock-
down and the average of twoRBP2 knockdown cellswere used for GSEAusing
GSEAv2.0software.Genesetsweregenerated frompublishedgenesignatures
(Bos et al., 2009; Kang et al., 2003; Minn et al., 2005, 2007). Statistical signifi-
cance was assessed by comparing the enrichment score with enrichment
results generated from 10,000 random permutations of the gene set. The log
rank (Mantel-Cox) test was used for analysis of tumor-free survival curves of
theMMTV-neu transgenicmice.Acomparisonof thenumberofmetastatic nod-
ules in lungs fromwild-type and Rbp2 knockout mice was performed using the
negative binomial model, and the t test was used for other statistical analyses.
Additional details regarding the methods used can be found in Supple-
mental Experimental Procedures.
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